Once GSK-3β could be considered as a potential therapeutic target for diabetes and neurological disorders due to its role in insulin pathway substrates and inflammation process [55, 56], western blot assays were performed to verify the presence of some age related changes in AKT and GSK-3β activity. The gene discussed is AKT1; the disease is nervous system disorder.